Anika TherapeuticsANIK
About: Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Employees: 357
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $46K | Put options by funds: $31K
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
2.93% less ownership
Funds ownership: 88.4% [Q3] → 85.47% (-2.93%) [Q4]
11% less funds holding
Funds holding: 122 [Q3] → 108 (-14) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
36% less capital invested
Capital invested by funds: $324M [Q3] → $206M (-$118M) [Q4]
48% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 27
Research analyst outlook
We haven’t received any recent analyst ratings for ANIK.
Financial journalist opinion









